Drug Patents owned by Leo Pharma As

1. List of Enstilar drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119781 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10688108 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10660908 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US9566286 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10716799 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10682364 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10617698 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10130640 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10130640

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(8 years from now)

US9119781

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 30, 2022
Pediatric Exclusivity (PED) Jan 30, 2023

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Market Authorisation Date: 16 October, 2015

Treatment: Plaque psoriasis; Topical treatment of plaque psoriasis in patients 12 years and older

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of ENSTILAR before it's patent expiration?
More Information on Dosage

2. List of Finacea drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900554 LEO PHARMA AS Foamable composition and uses thereof
Oct, 2023

(8 months from now)

US10322085 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Oct, 2023

(8 months from now)

US8722021 LEO PHARMA AS Foamable carriers
Oct, 2023

(8 months from now)

US8435498 LEO PHARMA AS Penetrating pharmaceutical foam
Mar, 2024

(1 year, 29 days from now)

US7700076 LEO PHARMA AS Penetrating pharmaceutical foam
Sep, 2027

(4 years from now)

US10117812 LEO PHARMA AS Foamable composition combining a polar solvent and a hydrophobic carrier
Oct, 2027

(4 years from now)

US9265725 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Dec, 2027

(4 years from now)

US9211259 LEO PHARMA AS Antibiotic kit and composition and uses thereof
Feb, 2029

(6 years from now)

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 29 July, 2015

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of FINACEA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in